The Role of Epiretinal Membrane on Treatment of Neovascular Age-Related Macular Degeneration with Intravitreal Bevacizumab
Table 2
Mean best corrected visual acuity and central retinal thickness values at baseline and at the 3-, 6-, 12-, and 24-month follow-up for AMD and AMD/ERM groups.
AMD group
value
AMD/ERM group
value
Mean baseline BCVA, logMAR SD (range)
(0.3–1.3)
(0.3–1.3)
Mean BCVA at 3 months, logMAR SD (range)
(0.2–1.0)
0.02
(0.3–1.1)
0.03
Mean BCVA at 6 months, logMAR SD (range)
(0.3–1.0)
0.11
(0.3–1.1)
0.13
Mean BCVA at 12 months, logMAR SD (range)
(0.3–1.0)
0.13
(0.3–1.2)
0.21
Mean BCVA at 24 months, logMAR SD (range)
(0.3–1.0)
0.39
(0.3–1.3)
0.52
Mean baseline CRT, m SD (range)
(275–462)
(298–519)
Mean CRT at 3 months, m SD (range)
(172–284)
<0.001
(221–353)
<0.001
Mean CRT at 6 months, m SD (range)
(178–299)
<0.001
(263–367)
<0.001
Mean CRT at 12 months, m SD (range)
(160–312)
<0.001
(232–380)
<0.001
Mean CRT at 24 months, m SD (range)
(153–302)
<0.001
(240–391)
<0.001
AMD, age-related macular degeneration; ERM, epiretinal membrane; BCVA, best corrected visual acuity; CRT, central retinal thickness; SD, standard deviation.
*One-way ANOVA test for all comparisons.